Literature DB >> 10751039

Nasal epithelial permeation of thymotrinan (TP3) versus thymocartin (TP4): competitive metabolism and self-enhancement.

M C Schmidt1, W Rubas, H P Merkle.   

Abstract

PURPOSE: To investigate concentration dependent permeabilities and metabolism kinetics of thymotrinan (TP3) versus thymocartin (TP4) in nasal epithelium in vitro.
METHODS: Excised bovine nasal mucosa was used as an in vitro model. Permeabilities were studied in a diffusion chamber, metabolism kinetics in a reflection kinetics set-up. Studies were performed at various TP3 and TP4 concentrations. The 3H-mannitol flux was measured to monitor junctional permeability. Potential Ca(2+)-complexation was investigated using a Ca(2+)-selective electrode.
RESULTS: Permeability of TP3 was negligible at 0.1 and 0.2 mM and increased drastically above 0.4 mM up to -2 X 10(-5) cm s(-1). In the presence of 2 mM TP4 the TP3 permeabilites were significantly above (approximately 4 x 10(-5) cm s(-1)) the level of TP3 without TP4, and TP3 metabolism was totally inhibited. TP3 and TP4 showed a significant concentration dependent effect on the permeability of 3H-mannitol. A hyperosmolarity effect of the peptide solutions was excluded. Transepithelial electrical resistance (TEER; approximately 30 ohms cm2) was unchanged by either TP3 or TP4. At 1 mM TP3 the mucosal-to-serosal permeability was four times higher than serosal-to-mucosal, indicating enzyme polarization. In reflection kinetics studies, TP3 degradation was slightly higher on the mucosal than on the serosal side. TP3 and TP4 followed the same non-linear metabolism kinetics.
CONCLUSIONS: Increase in permeability at high TP concentrations involves competitive enzyme saturation combined with self-enhanced paracellular permeation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751039     DOI: 10.1023/a:1007529716926

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

Review 1.  Recent progress in protein and peptide delivery by noninvasive routes.

Authors:  L L Wearley
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1991       Impact factor: 4.889

2.  Hydrolysis of peptides in the nasal cavity of humans.

Authors:  A A Hussain; K Iseki; M Kagoshima; L W Dittert
Journal:  J Pharm Sci       Date:  1990-10       Impact factor: 3.534

Review 3.  The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins.

Authors:  A Bernkop-Schnürch
Journal:  J Control Release       Date:  1998-03-02       Impact factor: 9.776

4.  Proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix assisted laser desorption ionization mass spectrometry (MALDI).

Authors:  S R Lang; W Staudenmann; P James; H J Manz; R Kessler; B Galli; H P Moser; A Rummelt; H P Merkle
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

5.  The influence of new thymopoietin derivatives on the immune response of inbred mice.

Authors:  E Rajnavölgyi; J Kulics; M Szilágyvári; L Kisfaludy; O Nyéki; I Schön; J Gergely
Journal:  Int J Immunopharmacol       Date:  1986

6.  Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa.

Authors:  S Lang; P Langguth; R Oschmann; B Traving; H P Merkle
Journal:  J Pharm Pharmacol       Date:  1996-11       Impact factor: 3.765

Review 7.  Aminopeptidases: structure and function.

Authors:  A Taylor
Journal:  FASEB J       Date:  1993-02-01       Impact factor: 5.191

8.  Permeation and pathways of human calcitonin (hCT) across excised bovine nasal mucosa.

Authors:  S Lang; B Rothen-Rutishauser; J C Perriard; M C Schmidt; H P Merkle
Journal:  Peptides       Date:  1998       Impact factor: 3.750

9.  Therapeutic possibilities of thymopoietin fragments (TP3 and TP4) based on experimental animal models.

Authors:  L Dénes; B Szende; G Hajós; L Szporny; K Lapis
Journal:  Drugs Exp Clin Res       Date:  1987

10.  Structural requirements for the biological activity of thymopentin analogs.

Authors:  G A Heavner; T Audhya; D Kroon; G Goldstein
Journal:  Arch Biochem Biophys       Date:  1985-10       Impact factor: 4.013

View more
  4 in total

1.  Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist.

Authors:  Kavitha Koushik; Nagesh Bandi; Sneha Sundaram; Uday B Kompella
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

2.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1).

Authors:  Kavitha Koushik; Gangadhar Sunkara; Peter Gwilt; Uday B Kompella
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

4.  Synthesis, Characterization and In Vitro Evaluation of a Novel Glycol Chitosan-EDTA Conjugate to Inhibit Aminopeptidase-Mediated Degradation of Thymopoietin Oligopeptides.

Authors:  Jiao Feng; Yan Chen; Feng Li; Lili Cui; Nianqiu Shi; Wei Kong; Yong Zhang
Journal:  Molecules       Date:  2017-07-26       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.